{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:43Z","timestamp":1785466723962,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01428-8","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:15:27Z","timestamp":1783181727000},"page":"2775-2796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences and Perspectives on Diabetic Retinopathy Screening and Treatment in Mexico: A Subanalysis of the Diabetic Retinopathy Barometer Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-2356","authenticated-orcid":false,"given":"Ingrid Y.","family":"Pita-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-4578","authenticated-orcid":false,"given":"Raul","family":"Velez-Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-799X","authenticated-orcid":false,"given":"Marlon","family":"Garc\u00eda Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz J.","family":"P\u00e9rez Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8577-9807","authenticated-orcid":false,"given":"Luis F.","family":"Rosales Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"10 Suppl","key":"1428_CR1","first-page":"s284","volume":"22","author":"NM Holekamp","year":"2016","unstructured":"Holekamp NM. Overview of diabetic macular edema. Am J Manag Care. 2016;22(10 Suppl):s284\u201391.","journal-title":"Am J Manag Care"},{"key":"1428_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et\u00a0al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"1428_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"issue":"3","key":"1428_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004","volume":"7","author":"MJ Hossain","year":"2024","unstructured":"Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004.","journal-title":"Health Sci Rep"},{"issue":"3","key":"1428_CR5","first-page":"355","volume":"25","author":"ME Gonz\u00e1lez Villalpando","year":"1994","unstructured":"Gonz\u00e1lez Villalpando ME, Gonz\u00e1lez Villalpando C, Arredondo P\u00e9rez B, Stern MP. Diabetic retinopathy in Mexico. Prevalence and clinical characteristics. Arch Med Res. 1994;25(3):355\u201360.","journal-title":"Arch Med Res"},{"issue":"2","key":"1428_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/etm.2015.2520","volume":"10","author":"AC Cepeda-Nieto","year":"2015","unstructured":"Cepeda-Nieto AC, Esquivel-Contreras MT, Duran-I\u00f1iguez F, Salinas-Santander MA, Gallardo-Blanco HL, Esparza-Gonz\u00e1lez SC, et\u00a0al. High prevalence of diabetic retinopathy and lack of association with integrin \u03b12 gene polymorphisms in patients with type 2 diabetes from northeastern Mexico. Exp Ther Med. 2015;10(2):435\u201344.","journal-title":"Exp Ther Med"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/DMSO.S447658","volume":"17","author":"AC Garc\u00eda-Ulloa","year":"2024","unstructured":"Garc\u00eda-Ulloa AC, P\u00e9rez-Peralta L, Jaime-Casas S, Jim\u00e9nez-Corona A, Rivera-De La Parra D, Graue-Hern\u00e1ndez EO, et\u00a0al. Risk factors associated with diabetic retinopathy with and without macular edema in recently diagnosed patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2024;17:231\u20138.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"1428_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/ijem.ijem_480_21","volume":"26","author":"BAM Mounirou","year":"2022","unstructured":"Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic retinopathy: an overview of treatments. Indian J Endocrinol Metab. 2022;26(2):111\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"1428_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.2147\/OPTH.S285955","volume":"14","author":"A Henaine-Berra","year":"2020","unstructured":"Henaine-Berra A, Flores-Peredo V, Lopezcarasa-Hernandez G, Martinez-Castellanos MA, Mira-Lorenzo X, Solis-Vivanco A, et\u00a0al. Survey of intravitreal injection techniques among retina specialists in Mexico. Clin Ophthalmol. 2020;14:4089\u201398.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1428_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40942-022-00396-y","volume":"8","author":"FJ Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez FJ, Wu L, Bordon AF, Charles M, Lee J, Machewitz T, et\u00a0al. Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study. Int J Retina Vitreous. 2022;8(1):52.","journal-title":"Int J Retina Vitreous"},{"key":"1428_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206583","author":"O Vivanco-Rojas","year":"2023","unstructured":"Vivanco-Rojas O, L\u00f3pez-Letayf S, Londo\u00f1o-Angarita V, Maga\u00f1a-Guerrero FS, Buentello-Volante B, Garfias Y. Risk factors for diabetic retinopathy in Latin America (Mexico) and the world: a systematic review and meta-analysis. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12206583.","journal-title":"J Clin Med"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.diabres.2017.03.023","volume":"129","author":"D Cavan","year":"2017","unstructured":"Cavan D, Makaroff L, da Rocha FJ, Sylvanowicz M, Ackland P, Conlon J, et\u00a0al. The Diabetic Retinopathy Barometer Study: global perspectives on access to and experiences of diabetic retinopathy screening and treatment. Diabetes Res Clin Pract. 2017;129:16\u201324.","journal-title":"Diabetes Res Clin Pract"},{"key":"1428_CR14","unstructured":"Coalition TnBL. Standardisation of definitions. Available from: https:\/\/www.amdbarometer.org\/standardisation-definitions."},{"issue":"4","key":"1428_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/ceo.13706","volume":"48","author":"S Jackson","year":"2020","unstructured":"Jackson S, Stokes JP. Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines. Clin Exp Ophthalmol. 2020;48(4):477\u201385.","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"1428_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11606-014-3089-1","volume":"30","author":"JM Taber","year":"2015","unstructured":"Taber JM, Leyva B, Persoskie A. Why do people avoid medical care? A qualitative study using national data. J Gen Intern Med. 2015;30(3):290\u20137.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1428_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et\u00a0al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12(1):92.","journal-title":"Syst Rev"},{"issue":"5","key":"1428_CR18","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s40123-023-00750-9","volume":"12","author":"SJ Bakri","year":"2023","unstructured":"Bakri SJ, Delyfer MN, Grauslund J, Andersen S, Karcher H. Real-world persistence and treatment interval in patients with diabetic macular edema treated with anti-vascular endothelial growth factors in the USA. Ophthalmol Ther. 2023;12(5):2465\u201377.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1428_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12913-025-12379-4","volume":"25","author":"S Li","year":"2025","unstructured":"Li S, Pan J, Xu Y, Dai Z, Fang Q. Exploring the factors influencing the timely intravitreal anti-VEGF treatment in patients with diabetic macular edema: a qualitative interview study using the COM-B model. BMC Health Serv Res. 2025;25(1):302.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"1428_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","volume":"123","author":"S Mueller","year":"2016","unstructured":"Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123(4):876-83.","journal-title":"Ophthalmology"},{"issue":"1","key":"1428_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12(1):92","journal-title":"Syst Rev"},{"issue":"1","key":"1428_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40123-024-01060-4","volume":"14","author":"F Ziemssen","year":"2025","unstructured":"Ziemssen F, Sylvanowicz M, Amoaku WM, Aslam T, Eldem B, Finger RP, et\u00a0al. Improving clinical management of diabetic macular edema: insights from a global survey of patients, healthcare providers, and clinic staff. Ophthalmol Ther. 2025;14(1):229\u201346.","journal-title":"Ophthalmol Ther"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","volume":"191","author":"NM Holekamp","year":"2018","unstructured":"Holekamp NM, Campbell J, Almony A, Ingraham H, Marks S, Chandwani H, et\u00a0al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol. 2018;191:83\u201391.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1428_CR24","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1186\/s12889-020-09717-y","volume":"20","author":"EF Okonji","year":"2020","unstructured":"Okonji EF, Mukumbang FC, Orth Z, Vickerman-Delport SA, Van Wyk B. Psychosocial support interventions for improved adherence and retention in ART care for young people living with HIV (10-24\u2009years): a scoping review. BMC Public Health. 2020;20(1):1841.","journal-title":"BMC Public Health"},{"key":"1428_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192315468","author":"EF Okonji","year":"2022","unstructured":"Okonji EF, Wyk BV, Hughes GD, Mukumbang FC. Psychosocial support programme improves adherence and health systems experiences for adolescents on antiretroviral therapy in Mpumalanga Province, South Africa. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph192315468.","journal-title":"Int J Environ Res Public Health"},{"key":"1428_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.987936","volume":"10","author":"MC Mu\u00f1oz-Contreras","year":"2022","unstructured":"Mu\u00f1oz-Contreras MC, Segarra I, L\u00f3pez-Rom\u00e1n FJ, Galera RN, Cerd\u00e1 B. Role of caregivers on medication adherence management in polymedicated patients with Alzheimer\u2019s disease or other types of dementia. Front Public Health. 2022;10:987936.","journal-title":"Front Public Health"},{"key":"1428_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/iopn.iopn_6_23","volume":"20","author":"S Kaur","year":"2023","unstructured":"Kaur S, Baby R, Padhy S. Effectiveness of caregiver intervention for improving medication adherence on level of medication adherence and attitude toward medications among nonadherent patients with mental illness. Indian J Psychiatric Nursing. 2023;20:103\u201310.","journal-title":"Indian J Psychiatric Nursing"},{"issue":"1","key":"1428_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1186\/s12913-023-09869-8","volume":"23","author":"SH Sharkiya","year":"2023","unstructured":"Sharkiya SH. Quality communication can improve patient-centred health outcomes among older patients: a rapid review. BMC Health Serv Res. 2023;23(1):886.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1428_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger R, Eldem B, Talks S, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234-247","journal-title":"Ophthalmology"},{"issue":"4","key":"1428_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1037\/amp0000298","volume":"73","author":"MA Rosen","year":"2018","unstructured":"Rosen MA, DiazGranados D, Dietz AS, Benishek LE, Thompson D, Pronovost PJ, et\u00a0al. Teamwork in healthcare: key discoveries enabling safer, high-quality care. Am Psychol. 2018;73(4):433\u201350.","journal-title":"Am Psychol"},{"issue":"1","key":"1428_CR31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12913-024-11062-4","volume":"24","author":"J Jacobs","year":"2024","unstructured":"Jacobs J, Dougherty A, McCarn B, Saiyed NS, Ignoffo S, Wagener C, et\u00a0al. Impact of a multi-disciplinary team-based care model for patients living with diabetes on health outcomes: a mixed-methods study. BMC Health Serv Res. 2024;24(1):746.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1428_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PRS.0b013e3181de24bc","volume":"126","author":"CJ Pannucci","year":"2010","unstructured":"Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619\u201325.","journal-title":"Plast Reconstr Surg"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01428-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:03:55Z","timestamp":1785463435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01428-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ingrid Yazm\u00edn Pita Ortiz has received grants from Roche and Bayer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bayer, Roche, Abbvie, and Amgen; and support for attending meetings and\/or travel from Bayer and Roche. Raul Velez-Montoya has received grants from Alcon laboratories, Inc. and SUN Pharma; speaker fees from Hoffmann-La Roche AG; support for attending meetings (ARVO 2025) from SUN Pharma; and has been treasurer for MARVO (ARCO Mexican Chapter). Marlon Garc\u00eda Roa declares no conflicts of interest. Beatriz Jatziri P\u00e9rez Arag\u00f3n declares no conflicts of interest. Luis Fernando Rosales Rodr\u00edguez declares no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was designed and developed according to the Declaration of Helsinki and the World Health Organization\u2019s International Ethical Guidelines for Biomedical Research. While the survey is a Primary Market Research Survey (which does not require ethics committee approval), individual institutions assessed local requirements. Verbal informed consent was obtained from all participants. Because the survey was anonymous and did not collect personal identifying information, written consent was not required. However, consent was implied by voluntary completion of the survey, without coercion, financial incentive, or influence on medical care.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}